[{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories enters into a Licensing Agreement with Gilead Sciences for Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Fujifilm Toyama Chemical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fujifilm to Partner with Dr Reddy's to Sell Avigan Overseas as Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Fujifilm Diosynth Biotechnologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm to Begin Clinical Trials Testing Avigan in COVID-19 Patients in Kuwait","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr.Reddy\u2019S Launches Generic Version of Ciprodex","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of AVIGAN\u00ae (Favipiravir) in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Dr. Reddy\\'s Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RDIF and Dr. Reddy\u2019s to Cooperate on Clinical Trials and Supply of 100 million Doses of Sputnik V Vaccine to India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Laboratories Launches Over-the-Counter Eye Allergy Drop, the Store-Brand\nEquivalent of Pataday\u00ae, in US","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Cinacalcet Tablets in the U.S. Market","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's seeks DCGI nod to conduct phase-3 clinical trial of Russian COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Laboratories to submit a revised protocol for conducting clinical trials of Russian COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Biotechnology Industry Research Assistance Council","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Partners with Department of Biotechnology - BIRAC for Sputnik V Vaccine Clinical Trials in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Plans to Complete Phase 3 Trial of Sputnik V Covid Vaccine by March End","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhibition and Overall Survival Through a Combination of E7777 (Denileukin Diftitox) and an Immune Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark to Sell Select Anti-Allergy Brands to Dr Reddy\u2019s in Russia, Ukraine, Kazakhstan and Uzbekistan for its \u201cRyaltris\u201d Launch","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's and RDIF Commence Clinical Trials for Sputnik V Vaccine in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Appili Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's, Global Response Aid, and Appili Therapeutics announce the filing of an application for REEQONUS\u2122 Tablets for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Laboratories Reports that Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Global Response Aid FZCO","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s and GRA Announce Avigan Pivotal Studies Update Study for Hospitalized Moderate to Severe Cases in Kuwait Terminated","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy\u2019s is Pleased to Share that Sputnik V Showed Strong Efficacy, Immunogenicity and Safety Results in the Interim Phase-3 Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Capecitabine Tablets, USP in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch Of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's initiates process for Emergency Use Authorization of Sputnik V","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy\u2019s Gets Approval for Import of Russia\u2019s Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India Drug Regulator Asks Dr.Reddy's For More Data on Sputnik V Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Pregene","pharmaFlowCategory":"D","amount":"$162.5 million","upfrontCash":"Undisclosed","newsHeadline":"Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Ethypharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ethypharm Reinforces its Late-Stage R&D Pipeline with a Novel Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Journey Medical Corporation Enters into an Agreement with Dr. Reddy\u2019s Laboratories to Develop DFD-29 for the Treatment of Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Five Pharma Majors Collaborate for Clinical Trial of Oral Anti-Viral Drug Molnupiravir to Treat Mild Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Laboratories Announces Commercial Launch of 2DG","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Laboratories launches Icosapent Ethyl Capsules in US","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Labs Denied Approval for Final Trial of Russian-Made Sputnik Light","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"$6.0 million","newsHeadline":"BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB\u2122 for the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Labs Receives US FDA Approval for Generic Librax","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"$40.0 million","newsHeadline":"Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Oncology Immunotherapy (E7777) for Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioDelivery Sciences International Completes Acquisition of ELYXYB\u2122 for Acute Migraine Treatment in the U.S. and Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy\u2019s Labs Launches Generic Revlimid Capsules in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Labs Launches Copy of BI Drug; Move May Lead to Legal Battle","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy\u2019s Labs Receives US FDA Approval for Generic Revlimid","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Prestige BioPharma Pte Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prestige BioPharma and Dr. Reddy\u2019s Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy\u2019s Gets DCGI Nod for Molnupiravir, to Launch Soon","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck's Anti- Covid Pill 'Molflu' 5-Day Course to Cost \u20b9 1,400 In India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis India Limited Extends Access to Its Medicines in India by Signing Exclusive Sales and Distribution Agreement With Dr. Reddy\u2019s Laboratories","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Gets DCGI Nod for Single-Shot Sputnik Light Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mankind Pharma to Acquire Combihale and Daffy Brands From Dr Reddy's Laboratories","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Binnopharm Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Binnopharm Group Enters Into Agreement to Acquire Two Anti-Bacterial Brands From Dr. Reddy\u2019s in the Russia & CIS Region","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dr Reddy's Buys Novartis Cardiovascular Brand Cidmus in India for Rs 456 Crore","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"MediCane Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Launches Generic Methylprednisolone Sodium Succinate for Injection in US","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GARDP, Dr. Reddy\u2019s and Aurigene Pharmaceutical Services Limited Sign MOU for Antibiotic Access Through Collaborative Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Lab To Approach Regulator for Sputnik Light as Universal Booster Dose","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"HK inno.N","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy\u2019s Laboratories to Commercialise Novel Molecule Tegoprazan in India","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories Enters Into a Voluntary Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Announces the Re-Launch of Over-The-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve\u00ae in the U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT\u00ae (vasopressin injection, USP) Vials in the U.S. Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Ephedrine Sulfate Injection USP, 50 mg\/mL, Single-Dose Vial in the U.S. Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Launches Minoxidil for Women Following First-Ever Approval in India for The Treatment of Female Pattern Hair Loss","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of A Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Tablets, USP in the U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Announces the Re-Launch of Over-The-Counter Famotidine Tablets USP, 10 mg and 20 mg, Store-Brand Equivalent of Pepcid AC\u00ae in the U.S. Market","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Pyrimethamine Tablets USP, 25 mg, First-Wave Generic Version of Daraprim\u00ae in the U.S. Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s and RDIF Receive Approval to Conduct Clinical Trial for Sputnik V Vaccine in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of A Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. Market","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Announces the Launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, The Store Brand Version of Voltaren\u00ae Arthritis Pain in the U.S. Market","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Redyx in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg\/5 mL (50 mg\/mL) per Single-dose Syringe in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Penicillamine Capsules USP, 250 mg in the U.S. Market","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Received Approval of XEGLYZE\u2122 (abametapir) Lotion, 0.74%, in the U.S.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, The Store Brand Version of Nicorette\u00ae Lozenges in the U.S. Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Fujifilm Toyama Chemical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy\u2019s Partners With FUJIFILM and Global Response Aid for Avigan\u00ae (favipiravir), A Potential Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Sale of Hospital Products","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Urology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Slayback Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories Enters Into a Licensing Agreement with Slayback Pharma to Obtain Exclusive Rights in The First-To-File ANDA For the Private Label Version of Lumify in The U.S.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D\u00ae 24 Hr in the U.S. Market","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Slayback Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories Enters Into a Licensing Agreement with Slayback Pharma to Obtain Exclusive Rights in The First-To-File ANDA For the Private Label Version of Lumify\u00ae in The U.S.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"DNDi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services and DNDi To Explore Joint Opportunities to Develop Affordable and Life-Saving New Drugs for Neglected Tropical Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"N\/A","country":"INDIA","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"N\/A"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Successfully Completes Phase 1 Study Of DRL_TC, a Proposed Biosimilar of Tocilizumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Febuxostat Tablets in the U.S. Market","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Successfully Completes Full Set Of Clinical Studies Of Its Rituximab Biosimilar For Filing In The U.S., Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in The U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Launches In-House Palbociclib (PRIMCYV\u00ae) To Widen Access to High-Quality Breast Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy\u2019s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"INDIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces First-to-Market Launch of Naloxone Hydrochloride Injection USP, 2 mg\/2 mL (1 mg\/mL) Single-dose Prefilled Syringe in the U.S. Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Ltd. Related to BENDEKA (bendamustine hydrochloride)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Eris Lifesciences","pharmaFlowCategory":"D","amount":"$33.2 million","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy\u2019s Divests Certain Non-Core Brands in Dermatology in India to Eris Lifesciences to Focus on Strengthening Core","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","amount":"$728.3 million","upfrontCash":"Undisclosed","newsHeadline":"Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Gets CDSCO Panel Nod to Manufacture & Market Treprostinil Solution for Infusion","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of Jul","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories announces its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Gears up for Weight Loss Drug Study","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics, Inc. and Dr. Reddy\u2019s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Edity Therapeutics","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"$2.0 million","newsHeadline":"Dr. Reddy's Laboratories acquires Preferred A-1 shares of Edity Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"INDIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"MenoLabs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Announces the Acquisition of MenoLabs\u00ae, a Leading Women\u2019s Health and Dietary Supplements Portfolio of Brands","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Launches Versavo\u00ae (bevacizumab) in The UK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Pharmazz","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmazz Inc. and Dr. Reddy's Laboratories have Entered into a Licensing Agreement to Market Centhaquine (Lyfaquin) as a Resuscitative Agent for Hypovolemic Shock in India","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Enters into Exclusive Distribution Partnership with Sanofi Healthcare India Private Limited for Their Vaccine Brands in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy\u2019s Labs Gets Nod to Study Popular Weight Loss Medication","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Dr. Reddy\u2019s sign a marketing and distribution agreement for second brand of Vericiguat\u2122 in India","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SEC Recommends Approval to Dr Reddy's to Import and Market Anti-cancer Drug Toripalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg in the U.S.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Dr. Reddy\\'s Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nestl\u00e9 India and Dr. Reddy\u2019s to Form Joint Venture to Take Health Science Nutraceutical Portfolio to Consumers Across India and Other Agreed Territories","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Alvotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech, Dr. Reddy's Collaborate on Denosumab Biosimilar in US, EU, UK","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy\u2019s and Novartis sign distribution agreement for anti-diabetes products","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Haleon","pharmaFlowCategory":"D","amount":"$632.9 million","upfrontCash":"$579.8 million","newsHeadline":"Dr. Reddy's Acquire Nicotinell and Related Portfolio","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Ingenus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr Reddy's Signs In-Licensing Pact with Ingenus for Cancer Treatment Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zydus and Dr. Reddy\u2019s License Agreement for Co-Marketing Pertuzumab Biosimilar in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"}]
Find Clinical Drug Pipeline Developments & Deals by Dr. Reddy\'s Laboratories
Through the license agreement, Dr. Reddy’s will receive semi-exclusive rights from Zydus to co-market Womab (pertuzumab) in India for the treatment of HER2-positive breast neoplasms.
Through the acquisition, Reddy will leverage the NRT portfolio, which includes Nicotinell (nicotine) in various formats such as lozenges, patches, and gum, across all applicable global market.
Under the in-licensing pact, Dr Reddy's USA will commercialise the Cyclophosphamide injection, an alkylating drug indicated for treatment of malignant lymphomas, for the US market.
Novartis Pharma will be responsible for the supply of Galvus and Galvus Met to DRL. Galvus and Galvus Met are prominent assets in the Dipeptidyl Peptidase-4 (DPP4) inhibitor category.
The collaboration aims for commercialization of AVT03 (denosumab), a monoclonal antibody and a biosimilar to Prolia & Xgeva. It is a RANK ligand inhibitor, being evaluated in bone loss in adult men.
Oracea-Generic (doxycycline) is a tetracycline class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.
Through the agreement, the two companies will establish a joint venture aimed at introducing innovative nutraceutical brands to consumers. The Nestlé Group will license brands like Nature's Bounty (biotin), an approved nutritional supplement for hair, skin, and nails.
Loqtorzi (toripalimab-tpzi) is an anti-PD-1 monoclonal antibody, which is an approved product in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma.
Bayer has granted non-exclusive rights to Dr. Reddy’s under the brand name Gantra. Vericiguat, a sGC stimulator, in India, is indicated, along with guideline-based medical therapy, in adults with symptomatic chronic heart failure with reduced ejection fraction.
Under the arrangement, Dr. Reddy’s will have exclusive rights to promote and distribute Sanofi’s wellestablished and trusted paediatric and adult vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U.
Market Place
KEY PRODUCTS
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations. 
